RU2758007C2 - Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов - Google Patents

Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов Download PDF

Info

Publication number
RU2758007C2
RU2758007C2 RU2019102391A RU2019102391A RU2758007C2 RU 2758007 C2 RU2758007 C2 RU 2758007C2 RU 2019102391 A RU2019102391 A RU 2019102391A RU 2019102391 A RU2019102391 A RU 2019102391A RU 2758007 C2 RU2758007 C2 RU 2758007C2
Authority
RU
Russia
Prior art keywords
virus
nucleic acid
acid sequence
cell
molecule
Prior art date
Application number
RU2019102391A
Other languages
English (en)
Russian (ru)
Other versions
RU2019102391A3 (enExample
RU2019102391A (ru
Inventor
Люк ИВНИН
Митчелл Х. ФИНЕР
Original Assignee
Онкорус, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкорус, Инк. filed Critical Онкорус, Инк.
Publication of RU2019102391A publication Critical patent/RU2019102391A/ru
Publication of RU2019102391A3 publication Critical patent/RU2019102391A3/ru
Application granted granted Critical
Publication of RU2758007C2 publication Critical patent/RU2758007C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019102391A 2016-06-30 2017-06-30 Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов RU2758007C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357195P 2016-06-30 2016-06-30
US62/357,195 2016-06-30
PCT/US2017/040354 WO2018006005A1 (en) 2016-06-30 2017-06-30 Pseudotyped oncolytic viral delivery of therapeutic polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021127872A Division RU2021127872A (ru) 2016-06-30 2017-06-30 Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов

Publications (3)

Publication Number Publication Date
RU2019102391A RU2019102391A (ru) 2020-07-30
RU2019102391A3 RU2019102391A3 (enExample) 2021-01-26
RU2758007C2 true RU2758007C2 (ru) 2021-10-25

Family

ID=60787595

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019102391A RU2758007C2 (ru) 2016-06-30 2017-06-30 Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
RU2021127872A RU2021127872A (ru) 2016-06-30 2017-06-30 Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021127872A RU2021127872A (ru) 2016-06-30 2017-06-30 Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов

Country Status (13)

Country Link
US (3) US20180057594A1 (enExample)
EP (1) EP3478321A4 (enExample)
JP (3) JP2019519245A (enExample)
KR (1) KR20190035714A (enExample)
CN (1) CN109983121A (enExample)
AU (1) AU2017290828A1 (enExample)
BR (1) BR112019000015A2 (enExample)
CA (1) CA3029426A1 (enExample)
IL (2) IL263879B (enExample)
MX (1) MX2019000252A (enExample)
RU (2) RU2758007C2 (enExample)
SG (1) SG11201811600PA (enExample)
WO (1) WO2018006005A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10888549B2 (en) 2016-03-07 2021-01-12 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
US12121573B2 (en) 2019-07-14 2024-10-22 Tianxin Wang Methods and agents including STING agonist to treat tumor
KR20190139225A (ko) 2017-04-28 2019-12-17 머크 샤프 앤드 돔 코포레이션 암 치료제용 생물마커
ES3041991T3 (en) 2017-05-25 2025-11-17 Leidos Inc Pd-1 and ctla-4 dual inhibitor peptides
WO2019023483A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND USES THEREOF
TN2020000015A1 (en) 2017-08-03 2021-10-04 Amgen Inc Interleukin-21 muteins and methods of treatment
WO2019032866A1 (en) * 2017-08-09 2019-02-14 Ohio State Innovation Foundation ONCOLYTIC VIRUS CARRYING E-CADHERIN AND USES THEREOF
EP4403175A3 (en) 2017-09-08 2024-10-02 Amgen Inc. Inhibitors of kras g12c and methods of using the same
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
SG11202005605SA (en) 2018-01-12 2020-07-29 Amgen Inc Anti-pd-1 antibodies and methods of treatment
WO2019201169A1 (en) * 2018-04-15 2019-10-24 Salubris (Chengdu) Biotech Co., Ltd Antibodies binding pd-1 and uses thereof
KR102673591B1 (ko) 2018-04-15 2024-06-07 임비라 컴퍼니 리미티드 Pd-1에 결합하는 항체 및 그 용도
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
CN110819657B (zh) * 2018-08-10 2021-11-19 睿丰康生物医药科技(浙江)有限公司 一种减毒棒状病毒的制备方法及应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN120022352A (zh) * 2018-10-22 2025-05-23 联邦高等教育系统匹兹堡大学 Cxcr3的可切割激活剂及其使用方法
EP3880812A4 (en) * 2018-11-13 2022-09-07 Oncorus, Inc. ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
SG11202104675TA (en) 2018-11-21 2021-06-29 Mayo Found Medical Education & Res Adenoviruses and methods for using adenoviruses
AR117547A1 (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas
AU2020204989A1 (en) * 2019-01-04 2021-07-08 Elevatebio Technologies, Inc. Encapsulated RNA polynucleotides and methods of use
EP3911355A4 (en) * 2019-01-15 2022-06-01 Cornell University RECOMBINANT LUBRICINS AND COMPOSITIONS AND METHODS OF USE THEREOF
CN113646008A (zh) 2019-01-28 2021-11-12 罗德岛大学理事会 pHLIP®肽介导的细胞表面的表位束缚
MX2021009186A (es) * 2019-01-30 2021-09-08 Wistar Inst Captadores biespecificos de linfocitos t codificados por adn que se dirigen a antigenos de cancer y metodos de uso en tratamientos contra cancer.
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CA3176660A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
AU2020232264A1 (en) 2019-03-05 2021-08-26 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
CN119040363A (zh) * 2019-03-15 2024-11-29 河谷细胞有限公司 重组erIL-15 NK细胞
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CA3138527C (en) * 2019-04-29 2024-03-12 Mayo Foundation For Medical Education And Research Multivalent pd-l1 binding compounds for treating cancer
CA3141162A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
DE112020002641T9 (de) * 2019-05-31 2022-10-06 Guangzhou Virotech Pharmaceutical Co., Ltd. M1-Virusmutante und deren Verwendung
US20220280609A1 (en) * 2019-07-17 2022-09-08 The Regents Of The University Of California Combination cancer therapy agents and methods
KR20220078665A (ko) * 2019-10-10 2022-06-10 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 다중특이적 면역 세포 인게이저를 발현하는 종양용해 바이러스
IL292836A (en) 2019-11-12 2022-07-01 Actym Therapeutics Inc Platforms for administering bacteria that stimulate the immune system and their use for administering therapeutic products
EP4100030A4 (en) * 2020-02-07 2024-03-27 City of Hope ONCOLYTIC VIRUS COMPOSITIONS AND METHODS FOR TREATING CANCER
CN111759841A (zh) * 2020-06-03 2020-10-13 山西第三医学研究发展有限公司 一种用匹多莫德在抗新型冠状病毒感染中的应用
US20210386804A1 (en) * 2020-06-11 2021-12-16 Tibor Bakács Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients
CN113832114A (zh) * 2020-06-23 2021-12-24 南京大学 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用
CA3189692A1 (en) 2020-07-31 2022-02-03 Leidos, Inc. Lag3 binding peptides
AU2021324883A1 (en) 2020-08-12 2023-03-23 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
CN112143711B (zh) * 2020-09-29 2021-07-23 杭州荣谷生物科技有限公司 重组痘瘤病毒、药物组合物及其构建方法和应用
CA3198203A1 (en) 2020-10-12 2022-04-21 Leidos, Inc. Immunomodulatory peptides
WO2022148736A1 (en) * 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2022151078A1 (zh) * 2021-01-13 2022-07-21 嘉兴允英医学检验有限公司 溶瘤病毒及其应用
US20240358780A1 (en) * 2021-04-05 2024-10-31 Implicyte, Inc. Armed chimeric oncolytic viruses
CN113969266B (zh) * 2021-10-26 2023-10-13 山东大学齐鲁医院 一种重组溶瘤腺病毒及其应用
CN113980915B (zh) * 2021-11-04 2023-07-07 江苏省人民医院（南京医科大学第一附属医院） 一种新型的表达cxcl10的复制型溶瘤腺病毒和应用
EP4429682A2 (en) 2021-11-09 2024-09-18 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
CN114249836A (zh) * 2021-12-27 2022-03-29 上海鑫湾生物科技有限公司 双特异性t细胞衔接器、其重组溶瘤病毒及其用途
WO2023235596A1 (en) * 2022-06-03 2023-12-07 10X Genomics, Inc. Systems and methods for determining antigen binding specificity of antigen binding molecules
WO2024055022A2 (en) * 2022-09-08 2024-03-14 Virogin Biotech Canada Ltd Oncolytic virus expressing an immune cell engager for tumor targeting
TW202426648A (zh) * 2022-09-30 2024-07-01 大陸商蘇州亦諾微醫藥科技有限公司 用於血液癌治療的基因改造的i型單純皰疹病毒
US20240415978A1 (en) * 2023-06-14 2024-12-19 Flagship Pioneering Innovations V, Inc. Anellovectors for delivery of effectors to the central nervous system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140037584A1 (en) * 2006-09-15 2014-02-06 Children's Hospital Of Eastern Ontario Research Institute Inc. Oncolytic rhabdovirus
US20140193449A1 (en) * 2007-05-04 2014-07-10 University Health Network Compositions and methods for cancer treatment
RU2536931C2 (ru) * 2009-05-06 2014-12-27 Фундасио Институт Д`Инвестигасио Биомедика Де Бельвитге (Идибель) Онколитический аденовирус для лечения рака, его применение и фармацевтическая композиция, содержащая его
US20160000842A1 (en) * 2013-03-05 2016-01-07 Baylor College Of Medicine Oncolytic virus

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
JPH0668B2 (ja) 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
WO1998040475A1 (en) 1997-03-11 1998-09-17 Abbott Laboratories Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
WO1999006583A1 (en) 1997-07-31 1999-02-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
ATE305510T1 (de) 1997-12-17 2005-10-15 Immunex Corp Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
SI2112166T1 (sl) 1998-12-23 2019-05-31 Pfizer Inc. Človeška monoklonska protitelesa proti CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
JP2003530092A (ja) 2000-03-17 2003-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ヒトＦＡＰ−α−特異抗体
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
EP1381280B1 (en) 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
MXPA04003057A (es) 2001-10-04 2005-06-20 Immunex Corp Proteina 4 de enlace ul16.
KR100900249B1 (ko) 2001-12-07 2009-05-29 포항공과대학교 산학협력단 ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
BR0309254A (pt) 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
EP1537878B1 (en) 2002-07-03 2010-09-22 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1591527B1 (en) * 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
EP1596871A4 (en) 2003-02-28 2006-08-23 Drew M Pardoll T-CELL REGULATION
CA2518782A1 (en) 2003-03-12 2004-09-23 Duke University Oligonucleotide mimetics
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
KR100845354B1 (ko) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항－ｃｔｌａ－4 항체의 용도
JP5054522B2 (ja) 2004-08-20 2012-10-24 ヴィラリティクス リミテッド 血液ガンを治療するための方法および組成物
EP1793858A4 (en) 2004-09-08 2008-12-10 Univ Ohio State Res Found HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
EP1805213B1 (en) 2004-10-28 2015-11-18 University of Pittsburgh - Of the Commonwealth System of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
US20080160031A1 (en) 2005-01-17 2008-07-03 Viralytics Limited Method and Composition for Treatment of Neoplasms
SI2002003T1 (sl) 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Genski vektor, ki vsebuje mi-RNA
DK1907000T4 (da) 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
ES2532124T3 (es) 2005-12-16 2015-03-24 Amgen Research (Munich) Gmbh Medios y procedimientos para el tratamiento de enfermedades tumorales
JP2009521474A (ja) 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
AU2007241023B2 (en) 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
AU2007266306A1 (en) 2006-05-26 2007-12-06 Apollo Life Sciences Limited An isolated IL-12 molecule or chimeric molecules thereof
CN101104640A (zh) 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
JP2008066402A (ja) 2006-09-05 2008-03-21 Fujifilm Corp 撮像素子および撮像装置
EP2125032A4 (en) 2007-02-20 2011-02-23 Mayo Foundation CANCER TREATMENT WITH VIRAL NUCLEIC ACID
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8586028B2 (en) 2007-05-09 2013-11-19 Board Of Supervisors Of Lousiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
US9416165B2 (en) 2007-10-26 2016-08-16 The Regents Of The University Of California Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
EP2240204A1 (en) 2008-02-04 2010-10-20 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2009111892A1 (en) 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
NO2700405T3 (enExample) 2008-05-29 2018-09-01
GB0810912D0 (en) 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
CA2755245A1 (en) 2009-03-13 2010-09-16 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
JP2013523162A (ja) 2010-04-06 2013-06-17 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法
CA2795695A1 (en) 2010-04-09 2011-10-13 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
ES2655616T3 (es) 2010-08-13 2018-02-20 Roche Glycart Ag Anticuerpos anti-FAP y procedimientos de uso
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
HRP20182194T1 (hr) * 2011-09-08 2019-02-22 New York University Onkolitički herpes simpleks virus i njegova terapeutska uporaba
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
EP2591796A1 (en) 2011-11-10 2013-05-15 Universität Zürich Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
AU2012322999B2 (en) 2011-10-11 2017-08-10 Universitat Zurich Prorektorat Mnw Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy
LT2768524T (lt) 2011-10-17 2022-07-25 Io Biotech Aps Pd-l1 grindžiama imunoterapija
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
DK2806883T3 (da) 2012-01-25 2019-07-22 Dnatrix Inc Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
EP2964675B1 (en) * 2013-03-05 2018-06-20 Baylor College Of Medicine Engager cells for immunotherapy
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
ES3011466T3 (en) 2013-04-18 2025-04-07 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US20160163211A1 (en) 2013-05-16 2016-06-09 Pearson Education, Inc. Accessible content publishing engine
JP6588024B2 (ja) 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター
CA2940570A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
EP3552615B8 (en) 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
KR20170063946A (ko) 2014-10-08 2017-06-08 에프. 호프만-라 로슈 아게 Fap 및 dr5에 특이적인 이중특이성 항체와 화학요법제의 병용요법
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
ES2994611T3 (en) 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
AU2016369485B2 (en) * 2015-12-17 2024-02-01 Akamis Bio Limited Group B adenovirus encoding an anti-TCR-complex antibody or fragment
CA3010987A1 (en) 2016-01-08 2017-07-13 Replimune Limited Oncolytic herpes simplex virus type 1 strain
BR112018015390A2 (pt) 2016-01-27 2018-12-18 Oncorus, Inc. vetores virais oncolíticos e usos dos mesmos
PL3426271T3 (pl) 2016-03-10 2025-11-24 Cg Oncology, Inc. Sposoby leczenia guzów litych terapią skojarzoną
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP7200104B2 (ja) 2016-08-01 2023-01-06 ヴァイロジン バイオテック カナダ リミテッド 免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター
CN118436692A (zh) 2016-08-09 2024-08-06 图恩斯通有限合伙公司 表达il12的溶瘤弹状病毒
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
US20190275092A1 (en) 2016-11-01 2019-09-12 Dnatrix, Inc. Combination therapy for treatment of brain cancers
WO2018118967A1 (en) 2016-12-21 2018-06-28 Memgen, Llc Armed replication-competent oncolytic adenoviruses
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140037584A1 (en) * 2006-09-15 2014-02-06 Children's Hospital Of Eastern Ontario Research Institute Inc. Oncolytic rhabdovirus
US20140193449A1 (en) * 2007-05-04 2014-07-10 University Health Network Compositions and methods for cancer treatment
RU2536931C2 (ru) * 2009-05-06 2014-12-27 Фундасио Институт Д`Инвестигасио Биомедика Де Бельвитге (Идибель) Онколитический аденовирус для лечения рака, его применение и фармацевтическая композиция, содержащая его
US20160000842A1 (en) * 2013-03-05 2016-01-07 Baylor College Of Medicine Oncolytic virus

Also Published As

Publication number Publication date
EP3478321A1 (en) 2019-05-08
CN109983121A (zh) 2019-07-05
US20190048082A1 (en) 2019-02-14
RU2019102391A3 (enExample) 2021-01-26
IL263879A (en) 2019-01-31
US11078280B2 (en) 2021-08-03
JP2023174945A (ja) 2023-12-08
CA3029426A1 (en) 2018-01-04
IL282216A (en) 2021-05-31
JP2022048304A (ja) 2022-03-25
WO2018006005A1 (en) 2018-01-04
JP2019519245A (ja) 2019-07-11
US10604574B2 (en) 2020-03-31
SG11201811600PA (en) 2019-01-30
AU2017290828A1 (en) 2019-01-24
US20200157221A1 (en) 2020-05-21
EP3478321A4 (en) 2020-04-22
RU2019102391A (ru) 2020-07-30
RU2021127872A (ru) 2021-11-09
MX2019000252A (es) 2019-10-09
BR112019000015A2 (pt) 2019-04-24
US20180057594A1 (en) 2018-03-01
IL263879B (en) 2021-04-29
KR20190035714A (ko) 2019-04-03

Similar Documents

Publication Publication Date Title
RU2758007C2 (ru) Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
US20240207334A1 (en) Oncolytic viral delivery of therapeutic polypeptides
JP7510413B2 (ja) Ｂ細胞成熟抗原に特異的なキメラ抗原受容体を使用する処置方法
JP2024023318A (ja) 二重特異性抗体の組成物及びその使用方法
JP2022553200A (ja) ユニバーサル受容体療法のためのレトロウイルスベクター
KR20220017914A (ko) Bcma를 표적으로 하는 조작된 면역 세포 및 그의 용도
CN114007642A (zh) 嵌合受体及其使用方法
CN110831961A (zh) 用于免疫疗法的cd19组合物和方法
CN106687483A (zh) 使用人源化抗‑bcma嵌合抗原受体治疗癌症
CN113651893B (zh) 联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
CN115916223A (zh) 与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
KR20250095757A (ko) TGF-β 수용체 및 이의 사용 방법
JP2024516713A (ja) キメラ受容体およびその使用方法
CN114920841B (zh) 抗cd87抗体及其特异性嵌合抗原受体
TW202321287A (zh) 特異性靶向間皮素之經工程改造之免疫細胞及其用途
JP2021514188A (ja) Ｆｏｘｐ３標的因子組成物と養子細胞療法のための使用方法
KR20230124912A (ko) 키메라 수용체 및 이의 사용 방법
JP2023545517A (ja) キメラ受容体およびその使用方法
JP2025538171A (ja) 抗原結合ドメイン及びその使用方法
JP2025185029A (ja) 免疫療法のためのｃｄ１９組成物及び方法
Burchett et al. Boosting of CAR-T cells with rhabdovirus is limited by type I interferon and rapid contraction
JP2025513284A (ja) 抗原結合ドメインおよびその使用方法
JP2023526228A (ja) 膠芽腫を処置するための方法
HK40062446B (zh) 靶向bcma的工程化免疫细胞及其用途
NZ749647A (en) Pseudotyped oncolytic viral delivery of therapeutic polypeptides

Legal Events

Date Code Title Description
HC9A Changing information about inventors